Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AALL1732: Inotuzumab Ozogamicin for Newly Diagnosed High-Risk B-ALL
NCT03959085Phase 3Recruiting
- Sponsor
- Children's Oncology Group
- Start
- Oct 2019
- Primary completion
- Mar 2032
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of inotuzumab ozogamicin in B cell acute lymphoblastic leukemia (B-ALL) (4 arms), sponsored by Children's Oncology Group. Primary endpoint: Event-Free Survival at 5 years. Started Oct 2019; status: recruiting.
02
Drugs
inotuzumab ozogamicin
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT03959085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03959085.